StageZero Life Sciences
  • About
    • Our Science >
      • The Sentinel Principle
    • Publications
    • Board of Directors
    • Partners
    • Scientific Advisory Board
  • Cancer Testing
    • Aristotle-Test
    • Employers
  • Physicians
    • Establish an Account
    • Order Supplies
    • Copia Login
  • INVESTORS
    • Investor Relations
    • Press Releases
    • Investor FAQs
    • Events
    • In the News
  • Contact
    • Customer Support
    • Corporate HQ
    • Careers
    • Bill Payment

​​ColonSentry®

Harnessing the Power of Gene Expression 
for Early Colorectal Cancer Detection

ColonSentry®

The First Liquid Biopsy for Colorectal Cancer Detection
ColonSentry® is a proprietary liquid biopsy test that uses advanced gene expression (mRNA) technology for the early identification of Colorectal Cancer (CRC). ​ColonSentry, was the first liquid biopsy for CRC, using our patented Sentinel Principle Technology Platform and has been used on more than 100,000 patients nationwide. (1-3)

Why Get Tested?


Picture

​​​​

When Colorectal Cancer is found early, the five-year survival rate is 91%. When Colorectal Cancer is found late, the five-year survival rate is 14% (4). If your ColonSentry score is elevated, there is an increased probability you may have Colorectal Cancer. (1-3)

  • No Dietary Restrictions​
  • No Need to Handle Messy Stool
  • No Preparation Required 
  • No Time Off Work

For Patients

    The ColonSentry test can be ordered by a Care Oncology physician through the AVRT telehealth program. 

    Please complete the form below to get started.
Submit

If you're a physician who would like to offer this test in
​your practice please click the button below.
For Physicians

The Science

The ColonSentry® test uses quantitative real-time polymerase chain reaction (RT-PCR) to measure the RNA transcript expression of seven biomarker genes in a whole blood sample. Expression levels of six genes—ANXA3, CLEC4D, LMNB1, PRRG4, TNFAIP6, and VNN1—are each paired with the expression level of a reference gene, IL2RB, to create a genetic signature by which patients can be stratified for CRC risk. ​(3)

​ColonSentry
® specifically measures gene expression in whole blood. Tumors are known to affect the gene expression profiles of circulating leukocytes, including both myeloid cells (monocytes, macrophages, etc.) and lymphocytes (T cells, B cells, and natural killer cells).This occurs due to a unique interaction between tumor cells and the immune system that has been referred to as “cancer immunoediting.” Immunoediting comprises three stages: elimination (in which the immune system identifies cancerous and/or precancerous cells and attempts to eradicate them), equilibrium (in which the surviving tumor cells begin mutating rapidly under selection pressure from immune-system-mediated attacks), and escape (in which tumor cells that have acquired resistance proliferate uncontrollably, leading to tumor progression). ​(5)
Validation
  • 9,000+ Patient Study North America (1)
  • 100,000+ Tests Performed in U.S. (3)
  • Finds Right & Left Sided Cancers (1)​
PUblications
Picture

​"The clinical utility of ColonSentry is significant. A routine blood test for patients who have yet to comply with any form of colorectal cancer screening can be a game-changer in identifying those at elevated risk for the disease and motivating them to have their colonoscopy. In addition, routine use of a blood test that detects both left-sided and right-sided lesions can increase the effectiveness of colorectal cancer screening by revealing the potential presence of neoplasms in advance of colonoscopy."

- Robert Burakoff, MD, Site Chief for the Division of Gastroenterology and Hepatology at New York-Presbyterian Lower Manhattan Hospital and Weill Cornell Medicine, 

References​​
  1. Chao S, Ying J, Liew G, et al. Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case- control study. J Exp Clin Cancer Res. 2013 Jul 23;32:44.Yip KT, Das PK, Suria D, et al.​
  2. Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006  Mar;147(3):126-32. 
  3. Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 2010 Mar 1;126(5):1177-86. 
  4. Seer.cancer.gov Dec 2019 * 5-year Survival Rate
Picture
StageZero Life Sciences. Ltd.
​30-70 East Beaver Creek Road
Richmond Hill, Ontario L4B 3B2

StageZero Life Sciences, Inc.
​8751 Park Central Drive, Suite 200
Richmond, VA 23227
​TEL: 855.420.7140 
Contact Information

Notice of Privacy Practices | Terms & Conditions | Privacy Statement & Policy | Licensing & Accreditation
  • About
    • Our Science >
      • The Sentinel Principle
    • Publications
    • Board of Directors
    • Partners
    • Scientific Advisory Board
  • Cancer Testing
    • Aristotle-Test
    • Employers
  • Physicians
    • Establish an Account
    • Order Supplies
    • Copia Login
  • INVESTORS
    • Investor Relations
    • Press Releases
    • Investor FAQs
    • Events
    • In the News
  • Contact
    • Customer Support
    • Corporate HQ
    • Careers
    • Bill Payment